By Lim Yun Chong, SIECRC

There have been significant advances in the understanding, prevention and treatment of age-related macular degeneration (AMD) over the past decade. It is now possible to prevent progression of AMD to more advanced stages by appropriate dietary antioxidant supplementation. Neovascular AMD can also be effectively treated with substantial improvements in visual outcomes.

Polypoidal choroidal vasculopathy (PCV) is a unique subtype of neovascular AMD common among Asians. A question that has been controversial in ophthalmology for many years is this: Is PCV a subtype of neovascular AMD or a separate clinical entity? Even more importantly, does this distinction affect treatment and outcomes?

Dr Ajeet Madhav Wagle, Medical Director and Senior Consultant Ophthalmologist at International Eye Cataract Retina Centre, touched on the latest on these conditions when he spoke on “What’s New in Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy?” during the inaugural Singapore Primary Eye Care Symposium (SPECS) held at One Farrer Hotel & Spa on 11-12 September 2017.

In Asian populations, between 20% and 50% of patients who presented with macular exudation and haemorrhage were found to have PCV. As treatment approaches may vary, it is important to distinguish between neovascular AMD and PCV.

Dr Ajeet touched on the similarities and differences between both conditions as well as different imaging modalities that can assist practitioners to make the distinction between the two conditions. He also shared with delegates the latest developments in the treatment of the two sight-threatening conditions.